CN1250244C - Composition for preventing and treating hyperlipidemia - Google Patents
Composition for preventing and treating hyperlipidemia Download PDFInfo
- Publication number
- CN1250244C CN1250244C CN 03135570 CN03135570A CN1250244C CN 1250244 C CN1250244 C CN 1250244C CN 03135570 CN03135570 CN 03135570 CN 03135570 A CN03135570 A CN 03135570A CN 1250244 C CN1250244 C CN 1250244C
- Authority
- CN
- China
- Prior art keywords
- extract
- preventing
- ginsenoside
- treating
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition for preventing and treating hyperlipemia. The present invention is a medicinal acceptable preparation prepared from the following raw materials of the percentage by weight: 10 to 80% of panax notoginsenosides, 10 to 80% of ginkgo biloba extracts (ginkgetin and bilobalide), 10 to 60% of extract of red sange root (tanshinone) and pharmaceutic adjuvant materials. The present invention is mainly used for treating and preventing hyperlipemia (reducing total cholesterol, triglyceride and low-density lipoprotein and increasing high-density lipoprotein). The synergy and the complementation of all the medicines of the prescription are favorable for increasing obvious curative effects, both manifestations and root causes of diseases can be treated, and the purpose of preventing and treating cardiovascular/cerebrovascular diseases can be realized.
Description
Technical field
The present invention relates to a kind of compositions of preventing and treating hyperlipemia, specifically is the compositions of feedstock production with Chinese medicine.
Background technology
Cardiovascular disease is a kind of common frdquently encountered disease of middle-aged and elderly people, the sickness rate height, and the course of disease is long, and complication is many, and human health is had very big harm.According to statistics, about 1,530 ten thousand people of global blood cardiovascular death in 1996 account for 29% of total death toll, occupy the first place of the various causes of death.China suffers from now that the patient of hyperlipemia is about 6,000 ten thousand, and coronary heart disease that the cardiovascular diseases causes and apoplexy are main causes of death, and its common pathologic basis all is an atherosclerosis.Hyperlipidemia is exactly one of risk factor of cardiovascular disease, adopts active measure treatment hyperlipidemia, and is very important for life-saving and raising people's quality of life.
Existing Chinese medicine and western medicine with effect for reducing fat has several, Chinese medicine and animals and plants extraction medicine such as hypogastric lipid-lowering pill, buchu zhibituo, Xuezhikang, many rare Weikang capsule for curing etc., these several medicines are except that hypogastric lipid-lowering pill, other are several sees from its description, and what all have certain toxic and side effects, the side effect of Xuezhikang to show as gastrointestinal upset, stomach is scorching hot, stomachache has serum third paddy transaminase and creatine phosphokinase slightly not high by chance, can recover.Many rare Weikang capsule for curing are fish oil preparation, but its side effect anticoagulant, so clotting mechanism has obstacle and hemorrhage person to avoid usefulness.Chemical synthetic drug mainly contain this medicine of lescol see fluvastatin (lescol, fluvastatin is received, Novartis Pharma AG) to liver, kidney, skeleton, gestation, certain toxic and side effects is arranged, anemia of pregnant woman forbidding; Fenofibrate (lipanthyl, France makes) has operation to liver, renal function, and therefore, liver, renal dysfunction person and child, pregnant person should not take, and also can cause untoward reaction such as gastrointestinal upset, dyspepsia, skin allergy, myalgia; Provastain sheet (Pu Daitading sodium sheet, Sino-U.S. executes in Shanghai expensive precious pharmaceutical Co. Ltd), its untoward reaction are slight transaminase's rising, erythra, myalgia, headache, chest pain, nausea,vomiting,diarrhea, tired etc.; That its side effect of simvastatin (Cindy he fourth, Hangzhou Mo Shadong pharmaceutical Co. Ltd) has is nauseating, diarrhoea, erythra, dyspepsia, Pruritus, alopecia, dizzy, muscle spasm, myalgia, pancreatitis, paraesthesia, peripheral neurophaty, vomiting and anemia etc.
The vice-president of the Asian-Pacific area cardiovascular and cerebrovascular vessel Committee of Experts, " Chinese cardiovascular magazine " chief editor, the traditional medicine research center consultant Deng Kaibai of Ministry of Public Health Gerontological Research Center institute professor, the chairman of both sides of the Straits cardiovascular community, professor Xu Chengbin of Beijing Medical University have also corrected the mistaken ideas of people to cardiovascular and cerebrovascular disease, the old complaint of pointing out all kinds of cardiovascular and cerebrovascular disease is blood rather than blood vessel, and treating blood vessel and ignoring blood is to put the cart before the horse.Change in case pathologic takes place for people's blood constituent, blood function, blood flow etc., injured blood vessel endothelium at first causes that atherosis, thrombosis, blood vessel blockage, gangrenosum acne are hemorrhage, causes all kinds of cardiovascular and cerebrovascular disease.Blood vessel self cleaning ability will reduce greatly, thereby causes the generation of cardiovascular and cerebrovascular diseases such as atherosclerosis, hyperlipidemia, vascular hypertension.So the prevention cardiovascular and cerebrovascular disease at first should improve blood, repairs blood vessel again.And the change of blood constituent at first just is reflected on the blood fat.So appeal, prevention cardiovascular and cerebrovascular disease key is the control blood fat.
Chinese invention patent discloses " a kind of compound gingko-red sage tablet and preparation method thereof " (98110316.2), and the medicine that this invention relates to also is to prevent and treat cardiovascular disease, and its prescription mainly is made up of Radix Salviae Miltiorrhizae extractum, Radix Notoginseng, Folium Ginkgo extractum etc.Because it adopts is that primary Radix Notoginseng powder minces, Semen Ginkgo extrac and Radix Salviae Miltiorrhizae extract, its pharmaceutical compositions complexity, pharmacology is uncertain, does not also have data how to show its curative effect.
Chinese invention patent also discloses " a kind of natural composition and application thereof that prevents and treats cardiovascular disease " (00135783.2), the natto that this invention is produced when mainly producing Semen Sojae Preparatum by mycetogenetic statins material, fungus and antibacterial is received kinases, be selected from nano_scale particle of Herb Gynostemmae Pentaphylli, Radix Notoginseng, Radix Salviae Miltiorrhizae, Folium Ginkgo, Radix Puerariae, Rhizoma Chuanxiong, Flos Carthami or Fructus Crataegi and the sugar tolerance factor that yeast produces, its prescription is based on mycetogenetic statins material, is equipped with four kinds, three kinds or two kinds and combines.
Summary of the invention
The purpose of this invention is to provide a kind of compositions of preventing and treating hyperlipemia with hypercholesterolemia reducing, triglyceride reducing, high density lipoprotein increasing, reduction low density lipoprotein, LDL.
The medicine of preventing and treating cardiovascular disease of the present invention is the medicament that is formed by following percentage by weight feedstock production:
Radix Notoginseng total arasaponins 10～80%
Folium Ginkgo extract 10～80%
Radix Salviae Miltiorrhizae extract 10～60%
Above-described Radix Notoginseng total arasaponins contains ginsenoside Rb1, ginsenoside Rg1.Described Folium Ginkgo extract is ginkgetin and Semen Ginkgo lactone.Described Radix Salviae Miltiorrhizae extract is a TANSHINONES.
The effective ingredient of three kinds of monomer medicines that the present invention is used is respectively:
1, Radix Notoginseng total arasaponins contains that the ginsenoside Rb1 must not be less than 30%, panaxoside Rg l must not be less than 20%, and total active ingredient 〉=60% of ginsenoside Rb1, ginsenoside Rg1;
2, the active ingredient of Folium Ginkgo extract is ginkgetin 〉=24%+ Semen Ginkgo lactone 〉=6%;
3, Radix Salviae Miltiorrhizae extract (Tanshinone I I
A) effective ingredient 〉=0.25%.
Above-described extract is used modern crafts, and water is carried, alcohol extraction, supercritical carbon dioxide process, all can obtain the product of its purification.
And primary raw material in available above three, be equipped with the required adjuvant of dosage form, said dosage form on any section's pharmaceutics of making.
Of the present invention studies show that, root or reed head with panax araliaceae plant, total Saponin of obtaining through refining by the Radix Notoginseng total arasaponins technological process, be rich in a large amount of Rb1 and the Rg1 of middle amount, Rb1 and Rg1 can irritate the metabolism of user's blood fat and cholesterol, and Radix Notoginseng total arasaponins has resisting fatigue, anoxia enduring, blood fat reducing, many-sided strengthening by means of tonics effects such as blood viscosity lowering and human body immunity improving function.And can take safety non-toxic for a long time.
Of the present invention studies show that, Folium Ginkgo extract (ginkgetin+Semen Ginkgo lactone) can reduce cholesterol levels in the blood of human body, prevent arteriosclerosis, eliminate the deposition composition on the blood vessel wall, improve hemorheological property, remove free radical rapidly, prevent that effectively high-fat cell membrane is oxidized, or after the free radical pair cell destroys, recover the complete of cell membrane again.
Studies show that, Radix Salviae Miltiorrhizae extract (TANSHINONES) descends blood viscosity, the synthetic effect that suppresses the body inner cholesterol, and can stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, to cardiovascular system can increase coronary flow, improve blood microcirculation, antiplatelet gathering and thrombosis.These effects help improving blood circulation, strengthen hypoxia-bearing capability, and renal blood flow (RBF) is significantly increased, and renal function obviously improves.Can also significantly increase the discharge of carbamide in the urine, creatinine, sodium and Phos.
The present invention is with the said medicine reasonable compatibility, and its effect is complemented each other, and effect is better than single medicine.Be mainly used in treatment and prevention hyperlipemia, full side cooperates, and complementation is short mutually, Synergistic, and effect is remarkable, and treating both the principal and secondary aspects of a disease, can reach the purpose of control cardiovascular and cerebrovascular disease.
The present invention compares with existing technology, has following outstanding substantive distinguishing features and obvious improvement:
1, taking dose is little, each 0.6g, every day 2 times.The present invention is the natural drug compound preparation, preferred above-mentioned Chinese crude drug extract, and scientific and reasonable in addition compatibility cooperatively interacts each medicine, and Synergistic is obvious, and effect is remarkable.
2, curative effect height, through verification experimental verification, the present invention prevents and treats hyperlipemia (high density lipoprotein increasing reduces low density lipoprotein, LDL for hypercholesterolemia reducing, triglyceride reducing) instant effect, to the control cardiovascular and cerebrovascular disease, can play the effect for the treatment of both the principal and secondary aspects of a disease.
3, the present invention is raw materials used is easy to get, and the prescription science is fit to the health industrial policy that China prevents cardiovascular and cerebrovascular disease, and the moderate product price of producing is fit to suitability for industrialized production. and can make the numerous common people be easy to accept.
Medicine of the present invention is through Yunnan natural drug pharmacology major test chamber drug screening, design blood fat reducing model, with 200 gram rats, every group 10, raised medicine 7 days, carry out rat blood fat reducing contrast test with hyperlipidemia model group contrast and the medicine (Xuezhikang) good with the generally acknowledged lipid-lowering effect of gain the national patent, data are as follows: (the research well afoot of relevant test and expansion indication scope)
The present invention's (efficient lipidemia health) is to the influence of experimental hyperlipemia in rats blood lipid level
| Group | Dosage g.kg -1.d -1 | The TC T-CHOL | TG mmol.L -1 | HDL-C mmol.L -1 | The LDL-C low density lipoprotein, LDL |
| The normal control group | - | 1.83 ±0.39 | 0.64 ±0.17 | 0.69 ±0.15 | 0.55 ±0.10 |
| The hyperlipidemia model group | - | 10.72 ±2.23 | 1.28 ±0.27 | 0.60 ±0.08 | 4.64 ±1.02 |
| Efficient lipidemia health | 0.2 | 9.80 ±3.01 | 0.90** ±0.14 | 0.66 ±0.12 | 4.15 ±1.29 |
| 0.4 | 7.83** ±1.68 | 0.90** ±0.17 | 0.81** ±0.12 | 3.48* ±0.80 | |
| 0.6 | 6.99** ±1.09 | 0.90** ±0.28 | 0.86** ±0.09 | 3.15** ±0.66 | |
| Xuezhikang | 0.6 | 7.71** ±1.40 | 1.03* ±0.15 | 0.71* ±0.14 | 3.42** ±0.66 |
Blood fat reducing percentage ratio
| Group | Dosage | T-CHOL | Triglyceride | High density lipoprotein | Low density lipoprotein, LDL | ||||
| Hyperlipidemia model | 10.72 | 1.28 | 0.60 | 4.64 | |||||
| Efficient lipidemia health | 0.4 | 7.83** | Fall 27% | 0.90** | Fall 30% | 0.81** | Rise 35% | 3.48* | Fall 25% |
| 0.6 | 6.99** | Fall 35% | 0.90** | Fall 30% | 0.86** | Rise 43% | 3.15** | Fall 32% | |
| Xuezhikang | 0.6 | 7.71** | Fall 28% | 1.03* | Fall 20% | 0.71* | Rise 18% | 3.42** | Fall 26% |
Annotate: * P＜0.05 * * P＜0.01
*: effective * *: produce effects
The specific embodiment
Embodiment 1:
Select Radix Notoginseng extract Radix Notoginseng total arasaponins 10%, Folium Ginkgo extract (ginkgetin and Semen Ginkgo lactone) 70%, Radix Salviae Miltiorrhizae extract TANSHINONES 20% for use, after mixing with medicinal blender, be prepared as capsule by capsule filling machine.
Embodiment 2:
With Radix Notoginseng extract Radix Notoginseng total arasaponins 25%, Folium Ginkgo extract (ginkgetin and Semen Ginkgo lactone) 25%, Radix Salviae Miltiorrhizae extract TANSHINONES 50%, after medicinal blender mixing, be prepared as capsule by capsule filling machine.
Embodiment 3:
With extract Radix Notoginseng total arasaponins 70%, Folium Ginkgo extract ginkgetin and Semen Ginkgo lactone 10%, Radix Salviae Miltiorrhizae extract TANSHINONES 20%, add the starch excipient of medicine gross weight 25%, after mixing with medicinal blender, be tablet by the preparation of tablet make-up machine.
Above-mentioned three kinds of monomer medicines can be bought in pharmaceutical factory and obtain.
Claims (5)
1, a kind of medicine of preventing and treating cardiovascular disease is characterized in that it being three kinds of medicaments that effective ingredient is prepared from by following percentage by weight:
Radix Notoginseng total arasaponins 10～80%
Folium Ginkgo extract 10～80%
Radix Salviae Miltiorrhizae extract 10～60%.
2, control cardiovascular disease medicine according to claim 1 is characterized in that described Radix Notoginseng total arasaponins contains ginsenoside Rb1, ginsenoside Rg1.
3, control cardiovascular disease medicine according to claim 1 is characterized in that described Folium Ginkgo extract is ginkgetin and Semen Ginkgo lactone.
4, control cardiovascular disease medicine according to claim 1 is characterized in that institute's Radix Salviae Miltiorrhizae extract is a TANSHINONES.
5, control cardiovascular disease medicine according to claim 1, wherein:
1) Radix Notoginseng total arasaponins contains that the ginsenoside Rb1 must not be less than 30%, ginsenoside Rg1 must not be less than 20%, and total active ingredient 〉=60% of ginsenoside Rb1, ginsenoside Rg1;
2) active ingredient of Folium Ginkgo extract is ginkgetin 〉=24%+ Semen Ginkgo lactone 〉=6%;
3) Tanshinone I I in the Radix Salviae Miltiorrhizae extract
AEffective ingredient 〉=0.25%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135570 CN1250244C (en) | 2003-08-09 | 2003-08-09 | Composition for preventing and treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135570 CN1250244C (en) | 2003-08-09 | 2003-08-09 | Composition for preventing and treating hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1473607A CN1473607A (en) | 2004-02-11 |
| CN1250244C true CN1250244C (en) | 2006-04-12 |
Family
ID=34154703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03135570 Expired - Fee Related CN1250244C (en) | 2003-08-09 | 2003-08-09 | Composition for preventing and treating hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1250244C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101263908B (en) * | 2008-04-25 | 2011-12-21 | 北京市科威华食品工程技术有限公司 | Blood fat reducing soft capsule health care food and its preparation |
| CN105596836B (en) * | 2016-01-22 | 2019-05-21 | 杨晓虹 | A kind of onion compositions extracted from gingko biloba leaves with effect for reducing blood fat |
| CN106491706A (en) * | 2016-11-03 | 2017-03-15 | 云南中科本草科技有限公司北京分公司 | Ginkgo leaf capsule of red sage root |
-
2003
- 2003-08-09 CN CN 03135570 patent/CN1250244C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1473607A (en) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN100384467C (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN1224614A (en) | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN1931261B (en) | Blood pressure and blood lipid lowering capsule and its preparation process | |
| CN103083582A (en) | Medicine for treating hyperlipidemia | |
| CN1977908A (en) | Chinese medicine composition for treating cardio-cerebrovascular disease | |
| CN101297888A (en) | Medicament composition and preparation thereof | |
| CN102697982A (en) | Composition having auxiliary blood fat reducing effect and preparation method thereof | |
| CN102784248A (en) | Chinese medicine composition for preventing and treating alcoholic liver injury | |
| CN1250244C (en) | Composition for preventing and treating hyperlipidemia | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN101537160A (en) | Health product for toxicant elimination and beauty maintenance | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN102743458B (en) | Formula of health drug with effects blood fat regulating and immunity increasing | |
| CN102178798A (en) | Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1611232A (en) | Medicinal composition with main effect of antifatigue, radioresistance and melancholia-resistance and its preparing method | |
| CN1399999A (en) | Medicine for curing malignant turnor and its preparation method | |
| CN1440804A (en) | Antilipemic Chinese medicine | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN101375978A (en) | Medicinal composition for lowering blood fat | |
| CN1262297C (en) | Chinese medicine for treating irritable bowel syndrome and preparing method thereof | |
| CN103656012B (en) | A kind of preparation method treating treating coronary heart disease and angina pectoris compositions | |
| CN1293049A (en) | 'Shexingkeyu' capsule for treating cardiovascular and cerebrovascular diseases and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060412 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |